|本期目录/Table of Contents|

[1]李树斌,于 鸿,张耿月.厄洛替尼耐药的非小细胞肺癌细胞的差异表达mRNAs和lncRNAs分析[J].中华肺部疾病杂志,2020,(03):365-370.[doi:10.3877/cma.j.issn.1674-6902.2020.03.015]
点击复制

厄洛替尼耐药的非小细胞肺癌细胞的差异表达mRNAs和lncRNAs分析(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2020年03期
页码:
365-370
栏目:
药物与临床
出版日期:
2020-06-20

文章信息/Info

Title:
-
作者:
李树斌1; 于 鸿2; 张耿月2
102600 北京,中国中医科学院广安门医院南区内一科1 130012 长春,吉林省肿瘤医院 吉林省肿瘤防治研究所细胞生物研究室2
Author(s):
-
关键词:
非小细胞肺癌;  厄洛替尼耐药;  差异表达;  IncRNAs分析
Keywords:
-
分类号:
R734.2
DOI:
10.3877/cma.j.issn.1674-6902.2020.03.015
摘要:
-
Abstract:
-

参考文献/References:

1 Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30.
2 钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
3 陈艳丽, 王媛媛, 张 勇, 等. 中晚期非小细胞肺癌患者化疗前后T淋巴细胞亚群表达差异分析及临床意义[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(1): 13-17.
4 Lin JJ, Shaw AT. Resisting Resistance: Targeted Therapies in Lung Cancer[J]. Trends cancer, 2016, 2(7): 350-364.
5 Fustaino V, Presutti D, Colombo T, et al. Characterization of epithelial-mesenchymal transition intermediate/hybrid phenotypes associated to resistance to EGFR inhibitors in non-small cell lung cancer cell lines[J]. Oncotarget, 2017, 8(61): 103340-103363.
6 Presutti D, Santini S, Cardinali B, et al. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells[J]. PloS one, 2015, 10(11): e0143333.
7 Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks[J]. Genome Res, 2003, 13(11): 2498-2504.
8 Zhang X, Sun S, Pu JK, et al. Long non-coding RNA expression profiles predict clinical phenotypes in glioma[J]. Neurobiol Dis, 2012, 48(1): 1-8.
9 Xue W, Li L, Tian X, et al. Integrated analysis profiles of long non-coding RNAs reveal potential biomarkers of drug resistance in lung cancer[J]. Oncotarget, 2017, 8(38): 62868-62879.
10 Wu Y, Yu DD, Hu Y, et al. Genome-wide profiling of long non-coding RNA expression patterns in the EGFR-TKI resistance of lung adenocarcinoma by microarray[J]. Oncol Rep, 2016, 35(6): 3371-3386.
11 Yang J, Lin J, Liu T, et al. Analysis of lncRNA expression profiles in non-small cell lung cancers(NSCLC)and their clinical subtypes[J]. Lung cancer, 2014, 85(2): 110-115.
12 Qu L, Ding J, Chen C, et al. Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA[J]. Cancer cell, 2016, 29(5): 653-668.
13 Jin W, Chen L, Cai X, et al. Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1[J]. Oncol Rep, 2017, 37(1): 273-280.
14 Cheng N, Li X, Zhao C, et al. Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer[J]. Oncol Rep, 2015, 33(2): 833-839.
15 Dey BK, Mueller AC, Dutta A. Long non-coding RNAs as emerging regulators of differentiation, development, and disease[J]. Transcription, 2014, 5(4): e944014.
16 Liu Z, Sun M, Lu K, et al. The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1)expression[J]. PloS one, 2013, 8(10): e77293.
17 Liu J, Wan L, Lu K, et al. The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma[J]. PloS one, 2015, 10(5): e0114586.
18 Chen J, Zhang K, Song H, et al. Long noncoding RNA CCAT1 acts as an oncogene and promotes chemoresistance in docetaxel-resistant lung adenocarcinoma cells[J]. Oncotarget, 2016, 7(38): 62474-62489.
19 Ma P, Zhang M, Nie F, et al. Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer[J]. Biomed Pharmacother, 2017, 87: 20-26.
20 Xia L, Huang W, Tian D, et al. Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma[J]. Hepatology(Baltimore, Md), 2013, 57(2): 610-624.
21 Cheng N, Cai W, Ren S, et al. Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer[J]. Oncotarget, 2015, 6(27): 23582-23593.
22 Pan H, Jiang T, Cheng N, et al. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer[J]. Oncotarget, 2016, 7(31): 49948-49960.
23 Wang B, Jiang H, Wang L, et al. Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway[J]. Oncol Lett, 2017, 13(5): 3494-3500.
24 Shi X, Sun M, Liu H, et al. A critical role for the long non-coding RNA GAS5 in proliferation and apoptosis in non-small-cell lung cancer[J]. Mol Carcinog, 2015, 54(Suppl 1): E1-e12.
25 Dong S, Qu X, Li W, et al. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression[J]. J Hematol Oncol, 2015, 8: 43.
26 Byers LA, Diao L, Wang J, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance[J]. Clin Cancer Res, 2013, 19(1): 279-290.
27 Zhang Z, Lee JC, Lin L, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer[J]. Nat Genet, 2012, 44(8): 852-860.
28 Vajkoczy P, Knyazev P, Kunkel A, et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival[J]. Proc Natl Acad Sci U S A, 2006, 103(15): 5799-5804.

备注/Memo

备注/Memo:
基金项目: 吉林省卫生技术创新项目(2017J025)
更新日期/Last Update: 2020-06-20